Group 1 - The company held a performance briefing for the fiscal year 2024 and the first quarter of 2025 on June 13, 2025, via the Shanghai Stock Exchange's online platform [1] - Key executives, including the Chairman and General Manager, participated in the briefing to discuss the company's operational results and financial metrics with investors [2] - The company is focusing on enhancing its service capabilities and operational efficiency through digitalization and innovation, while also maintaining a commitment to cash dividends for investors [2] Group 2 - The company has established a strategic and ESG committee to integrate ESG governance into its board management, and it has been recognized for its ESG performance with an A rating in the market [2] - The company has been actively involved in various health-related retail formats, including health stations targeting young mothers and comprehensive health towns offering a range of health products and services [2] - The company has received accolades such as the "2024 Whale Award" for being an ESG newcomer, highlighting its commitment to sustainable development [2]

Core Points - The Shanghai First Pharmaceutical Co., Ltd. will hold its 2024 Annual General Meeting on June 20, 2025, with both on-site and online voting options available for shareholders [1][2][3] - The meeting will cover 12 proposals, including the annual report, board and supervisory reports, financial statements, and various governance matters [6][7][15] - The company emphasizes maintaining shareholder rights and ensuring orderly conduct during the meeting [4][5] Meeting Agenda - The meeting will start with attendance reporting and the announcement of the meeting's commencement [1] - Proposals will be read and discussed, followed by independent directors' reports and shareholder Q&A sessions [1][3] - Voting will occur after discussions, with results announced by the legal representative [1][6] Voting Procedures - Shareholders must present valid identification and may appoint proxies with proper authorization to vote [2][4] - Voting will be conducted through both on-site and online methods, with specific time frames for each [4][5] - Each proposal will be voted on individually, and any invalid votes will be counted as abstentions [5][6] Board and Supervisory Reports - The board's report will detail the company's operations and governance practices, highlighting compliance with legal and regulatory requirements [7][8][10] - The supervisory report will confirm the company's adherence to laws and regulations, ensuring the protection of shareholder interests [15][17] Financial Overview - The financial report for 2024 will be presented, including audited financial statements and budget proposals for 2025 [22] - The company has received a standard unqualified audit opinion from its accounting firm [22]

证券代码：600833 证券简称：第一医药 公告编号：临 2025-029 上海第一医药股份有限公司 2.请问公司如何鼓励科研人员创新？在激励制度方面做了哪些工作？能否 简单介绍一下？谢谢 关于 2024 年度暨 2025 年第一季度业绩说明会 召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海第一医药股份有限公司（以下简称"公司"）2024 年度暨 2025 年第一 季度业绩说明会于 2025 年 6 月 13 日（星期五）下午 15:00-16:00 通过上海证券 交易所上证路演中心（网址：http://roadshow.sseinfo.com/）以网络互动的方 式召开。现将本次说明会召开情况公告如下： 一、本次说明会召开情况 2025 年 6 月 6 日，公司在上海证券交易所网站（http://www.sse.com.cn） 披露了《关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告》（公告编号： 临 2025-028）。 公司党委书记、董事长张海波先生，党委副书记、副董事长、总经理姚军先 ...

上海第一医药股份有限公司 2024 年年度股东大会 会议资料 会议资料目录 | 一、2024 年年度股东大会会议议程 ……………………………………………1 | | --- | | 年年度股东大会会议须知 二、2024 ……………………………………………2 | | 三、2024 年年度报告及摘要 ……………………………………………………4 | | 年度董事会工作报告 四、2024 …………………………………………………5 | | 五、2024 年度监事会工作报告 …………………………………………………10 | | 年度财务决算及 六、2024 2025 年度财务预算报告……………………………14 | | 七、2024 年度利润分配预案 ……………………………………………………19 | | 八、关于与百联集团财务有限责任公司签订《金融服务协议》暨关联交易的议案………20 | | 九、关于 2024 年度董事薪酬情况的议案 ………………………………………24 | | 十、关于取消监事会并修订《公司章程》及配套制度的议案 ………………25 | | 十一、关于第十一届董事会独立董事津贴的议案 ……………………………26 ...

A股医药商业板块水下拉起，一心堂封板涨停，漱玉平民、健之佳、华人健康、第一医药、益丰药房等 跟涨。 ...

关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 6 月 13 日（星期五）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 证券代码：600833 证券简称：第一医药 公告编号：临 2025-028 上海第一医药股份有限公司 一、说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2024 年度及 2025 年第一 季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披 露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 6 月 13 日（星期五）下午 15:00-16:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 董事 ...

Core Viewpoint - Shanghai First Pharmaceutical Co., Ltd. has held its 33rd temporary board meeting, where several key resolutions were passed, including the proposal to abolish the supervisory board and amend the company's articles of association, as well as the nomination of candidates for the 11th board of directors [2][3][57]. Group 1: Board Meeting Resolutions - The board meeting was convened on May 30, 2025, with all 9 directors participating and no dissenting votes [2][4]. - The proposal to cancel the supervisory board and amend the articles of association was approved unanimously and will be submitted for review at the 2024 annual general meeting [3][4][57]. - The board proposed the nomination of Zhang Haibo, Yao Jun, Zhou Yu, Li Jinbiao, and Zhang Rui as candidates for the 11th board of directors (non-independent directors) [5][6]. - The independent director candidates proposed are Wang Feng, Tang Songlian, and Chen Shaoxiong, with their qualifications approved by the Shanghai Stock Exchange [8][9]. - The independent directors' remuneration was set at 80,000 yuan (including tax) per year, payable quarterly, and this proposal will also be submitted for the annual general meeting [12][14]. - A proposal to purchase liability insurance for directors, supervisors, and senior management was discussed, with the decision deferred due to conflicts of interest among the voting members [15][16][52]. Group 2: Value Management and Safety Regulations - The company aims to enhance its market value management and has proposed a value enhancement plan to reflect its investment value and improve shareholder returns [18][19]. - A proposal to establish safety production management regulations was also approved to ensure compliance with safety laws and promote sustainable development [20][21]. Group 3: Annual General Meeting Notification - The 2024 annual general meeting is scheduled for June 20, 2025, with both on-site and online voting options available for shareholders [29][30]. - The meeting will address various proposals, including those previously disclosed on the Shanghai Stock Exchange [31][32].

Meeting Information - The annual general meeting of Shanghai First Pharmaceutical Co., Ltd. is scheduled for June 20, 2025, at 13:30 [1] - The meeting will take place at the third conference room on the 20th floor, 681 Xiaomuqiao Road, Xuhui District, Shanghai [1] - Shareholders can vote through the Shanghai Stock Exchange's online voting system on the same day from 9:15 to 15:00 [1][2] Voting Procedures - Shareholders can participate in voting via both on-site and online methods [3] - The voting system allows shareholders with multiple accounts to aggregate their voting rights across all accounts [4] - Invalid votes will be counted if shareholders exceed their voting rights or vote more than the number of candidates in a differential election [4] Agenda Items - The meeting will discuss various proposals, including financial service agreements and related transactions [3][7] - Specific proposals will be disclosed on the Shanghai Stock Exchange website prior to the meeting [3] Attendance and Registration - Shareholders must register to attend the meeting, with specific requirements for corporate and individual shareholders [5] - Registration will be open on June 16, 2025, from 9:00 to 11:00 and 13:00 to 16:00 [5] Additional Information - The meeting is expected to last half a day, and attendees will bear their own travel and accommodation costs [6] - Contact information for the company's board office is provided for further inquiries [6]

Core Points - The company held its 19th (temporary) meeting of the 10th Supervisory Board on May 30, 2025, via communication methods, with all three supervisors participating in the vote [1][2] - The meeting approved the proposal to cancel the Supervisory Board and amend the Articles of Association and related systems, which will be submitted for review at the 2024 annual shareholders' meeting [1][2] - A proposal to purchase liability insurance for directors, supervisors, and senior management was also presented, but all supervisors abstained from voting due to being the insured parties, and this proposal will also be submitted for review at the 2024 annual shareholders' meeting [2][3] Voting Results - The proposal to cancel the Supervisory Board received unanimous support with 3 votes in favor, and no votes against or abstentions [2] - The proposal for liability insurance had no votes recorded as all supervisors abstained from voting [3]

独立董事候选人声明与承诺 本人唐松莲，已充分了解并同意由提名人上海第一医药股份 有限公司董事会提名为上海第一医药股份有限公司第十一届董 事会独立董事候选人。本人公开声明，本人具备独立董事任职资 格，保证不存在任何影响本人担任上海第一医药股份有限公司独 立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、部门规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的 规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部 辞去公职或者退（离）休后担任上市公司、基金管理公司独立董 事、独立监事的通知》的规定（如适用）； 业兼职（ ...